



Short Tandem Repeat Analysis

Requestor: WiCell Characterization

WTRIPath HISTOLOGY - IHC - MOLECULAR - IMAGING

TRIP Laboratory (Molecular)

(608) 265-9168

Department of Pathology and Laboratory Medicine

https://research.pathology.wisc.edu/trip-home/

Boston University - Aine Russell

Receive Date: 02/10/20 **Report Sent:** 02/17/20

Label on tube	SCN2 p.0 D01 (80242)
Label on Report	SCN2 p.0 D01 (80242)
conc (ng/µL)	111.9
A260/280	1.96
Assay Date	2/11/2020
File Name	STR 200212 wmr
FGA	23,24
ΤΡΟΧ	8,9
D8S1179	12,13
vWA	15,16
Amelogenin	X,X
Penta_D	2.2,12
CSF1PO	12,12
D16S539	9,10
D7S820	8,11
D13S317	12,12
D5S818	12,13
Penta_E	5,15
D18S51	13,20
D21S11	28,29
TH01	7,7
D3S1358	15,16
Allelic Polymorphisms	27
Matches*	
Comments	





Your Lab Partner characterization@wicell.org (608) 316-4145

Short Tandem Repeat Analysis

<u>Results</u>: Based on the DNA submitted by WiCell Characterization Department for Boston University - Aine Russell dated and received on 02/10/20, these samples define the STR profiles of the human cell lines as indicated by name. The genotypic profiles comprise a range of 24-29 allelic polymorphisms across the 15 STR loci analyzed.

Interpretation: The concentration of DNA required to achieve an acceptable STR genotype (signal/ noise) was equivalent to that required for the standard procedure (~1 ng/amplification reaction) from human genomic DNA. These results suggests that the cells submitted correspond to the cell lines as named and were not contaminated with any other human cells or a significant amount of mouse feeder layer cells.

Sensitivity: Sensitivity limits for detection of STR polymorphisms unique to either this or other human cell lines is ~2-5%.

* Note: The STR profile of the following sample is an exact match for the given sample/samples.

X RMB

Rebecca M. Baus, BA

TRIP Laboratory, Molecular

Digitally Signed on 02/17/20

X WMR Digitally Signed on 02/17/20

William M. Rehrauer, PhD, Director / Co-Director UWHC Molecular Diagnostics Laboratory / UWSMPH TRIP Laboratory

Testing was accomplished by analysis of human genetic polymorphisms at STR loci. This methodology has not yet been approved by the FDA and is for investigational use only. Acknowledge TRIP in your publications, posters & presentations. For details, see: https://research.pathology.wisc.edu/acknowledging-trip/

Unless otherwise mutually agreed in writing, the services provided to you hereunder by WiCell Research Institute, Inc. ("WiCell") are governed solely by WiCell's Terms and Conditions of Service, found at https://www.wicell.org/media.acux/ca76d97c-862a-43f3-b02a-ab2d1e619100. Any terms you may attach to a purchase order or other document that are inconsistent, add to, or conflict with WiCell's Terms and Conditions of Service are null and void and of no legal force or effect.

Page 2